Health technology appraisal

• 6th Jan 2026

  Review of “Capturing the Impact of Constraints on the Cost-Effectiveness of Cell and Gene Therapies: A Systematic Review”

• 10th Nov 2025

  Preferences for advanced therapy medicinal products: understanding the published literature on the value of innovative health interventions

• 29th Sep 2025

  Should uncertainty be considered a value attribute in its own right or as an inherent component of other attributes as part of value assessment frameworks?

• 15th Sep 2025

  Value attributes of advanced therapy medicinal products: a comprehensive literature review

• 23rd Jun 2025

  The value of hope – the case against inclusion in a value assessment framework for advanced therapies 

• 10th Mar 2025

  A Perspective on ‘Evolving Concept of Value in Health Economics and Outcomes Research: Emerging Tools for Innovation and Access to Cell and Gene Therapies for Rare Diseases’

• 2nd Sep 2024

  A case study of the challenges of demonstrating cost-effectiveness in under-served patient populations: lecanemab for treating mild cognitive impairment or mild dementia caused by Alzheimer’s disease

• 19th Jun 2024

  Issues, Challenges and Opportunities for Economic Evaluations of Orphan Drugs in Rare Diseases: An Umbrella Review

• 17th Jun 2024

  Identifying value elements of advanced therapy medicinal products: An opportunistic review of stakeholder responses submitted to NICE as part of reimbursement decision making

• 27th Dec 2020

  The need for pragmatic updates to the NICE methods